Wells Fargo & Company Biodesix Inc Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BDSX
# of Institutions
58Shares Held
62.3MCall Options Held
2.6KPut Options Held
10.1K-
Telemark Asset Management, LLC Boston, MA8.28MShares$11.4 Million1.58% of portfolio
-
Bryn Mawr Trust CO Bryn Mawr, PA6.1MShares$8.41 Million0.2% of portfolio
-
Aigh Capital Management LLC Baltimore, MD5.68MShares$7.84 Million4.09% of portfolio
-
Birchview Capital, LP Burlington, VT5.54MShares$7.65 Million9.1% of portfolio
-
Farallon Capital Management LLC San Francisco, CA4.64MShares$6.4 Million0.04% of portfolio
About BIODESIX INC
- Ticker BDSX
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 39,982,000
- Market Cap $55.2M
- Description
- Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pat...